IBI3002 Safety Study in Healthy and Asthmatic Participants Underway
A randomized, double-blind, placebo-controlled study is evaluating the safety and tolerability of IBI3002 in healthy participants and asthma patients.
Indication
Clinical and regulatory intelligence for Asthma with 21 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.